Perkovic, Vlado

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 7,830

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 6,189

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 2,099

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,084

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Rahimi, K., Bidel, Z., Nazarzadeh, M., Copland, E., Canoy, D., Ramakrishnan, R., Pinho-Gomes, A.-C., Woodward, M., Adler, A., Agodoa, L., et al. (2021) · The Lancet

Blood Pressure and Hypertension StudiesSodium Intake and Health

Cited by 1,074

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,020

Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis

Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G. S., et al. (2016) · The Lancet

Blood Pressure and Hypertension StudiesSodium Intake and Health

Cited by 980

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes

Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 965

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 927

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 893

Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis

Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA

Blood Pressure and Hypertension StudiesDiabetes Treatment and Management

Cited by 854

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 637

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes

Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 626

Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency

Levey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 591

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 498

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 488

Guideline for the diagnosis and management of hypertension in adults - 2016

Gabb, G. M., Mangoni, A. A., Anderson, C. S., Cowley, D., Dowden, J. S., Golledge, J., Hankey, G. J., Howes, F. S., Leckie, L., Perkovic, V., et al. (2016) · Medical Journal of Australia

Blood Pressure and Hypertension StudiesClinical practice guidelines implementation

Cited by 406

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 397

Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis

Yu, J., Zhou, Z., McEvoy, R. D., Anderson, C. S., Rodgers, A., Perkovic, V., & Neal, B. (2017) · JAMA

Obstructive Sleep Apnea ResearchSleep and related disorders

Cited by 371

Canagliflozin slows progression of renal function decline independently of glycemic effects

Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 361

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., et al. (2025) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 359

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Neuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 358

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

Coresh, J., Heerspink, H. J. L., Sang, Y., Matsushita, K., Arnlov, J., Astor, B. C., Black, C., Brunskill, N. J., Carrero, J.-J., Feldman, H. I., et al. (2019) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 338

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis

Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 330